IHC - CD21

The tissue sample for this test is usually obtained through a biopsy procedure, which involves removing a small piece of tissue for analysis under a microscope.

No, this test requires a tissue sample that needs to be collected by a healthcare professional and analyzed in a laboratory.

The turnaround time for results is typically 3-5 days, but this can vary depending on the laboratory.

The IHC - CD21 test can be used in diagnosing certain types of lymphomas, as well as some autoimmune disorders. However, the test is generally not used on its own and will be part of a larger panel of tests to reach a diagnosis.

A negative result means that the CD21 protein was not detected in the tissue sample. This could suggest that the condition in question does not involve CD21-expressing cells. However, your healthcare provider will interpret these results in the context of your symptoms and other test results.

The risks associated with this test are primarily linked to the biopsy procedure used to collect the tissue sample. These risks can include pain, bleeding, or infection at the site of the biopsy. The test itself does not pose any risks.

Yes, in some cases, the IHC - CD21 test can be used to monitor the progression of a disease or the response to treatment. However, the specifics will depend on the individual patient's condition and the judgment of the healthcare provider.

Yes, the IHC - CD21 test is often performed in conjunction with other immunohistochemical tests, flow cytometry, or genetic tests to aid in diagnosing and classifying certain diseases.

The IHC - CD21 test is typically performed on a tissue sample obtained through a biopsy. It is not usually done on a blood sample.

If your results are inconclusive, your healthcare provider may recommend additional testing to help reach a diagnosis. This could include repeating the IHC - CD21 test or doing other related tests.

While a positive IHC - CD21 test can indicate the presence of certain diseases, it is not used alone for a definitive diagnosis. Other tests and clinical information will be considered by your healthcare provider to confirm a diagnosis.

The IHC - CD21 test can help in distinguishing between different types of lymphomas by identifying the presence or absence of CD21-expressing cells. However, it's typically used in conjunction with other diagnostic tools for a comprehensive understanding of the disease.

The IHC - CD21 test is a reliable method for detecting CD21 protein in tissue samples. However, the reliability also depends on the quality of the tissue sample and the expertise of the laboratory performing the test.

While the primary use of the IHC - CD21 test is for diagnosing certain lymphomas and autoimmune conditions, it may also be used in a research setting or for diagnosing other less common conditions.

No specific preparation is required for the IHC - CD21 test. However, you should discuss any medications or supplements you're taking with your healthcare provider as they could potentially impact the test results.

Once the tissue sample has been obtained via biopsy, it can be processed and tested relatively quickly. The exact timeline will depend on the laboratory.

Yes, the IHC - CD21 test may be repeated to assess the effectiveness of treatments, particularly those targeting CD21-expressing cells.

Yes, there are no dietary restrictions before the IHC - CD21 test as it does not require a blood sample. However, certain medications or supplements may need to be avoided, so be sure to discuss this with your healthcare provider.

The interpretation of IHC - CD21 test results should be done by a healthcare professional. They will consider these results in combination with other diagnostic tests and clinical findings to provide a comprehensive diagnosis.

The IHC - CD21 test is primarily used to identify certain types of lymphomas and some autoimmune conditions. It's not typically used to detect other types of cancer, but research into additional uses is ongoing.